Not long after its acquisition by Sanofi, Protein Sciences is bidding adieu to its former leader. Yet Manon Cox says the departure wasn’t on her terms, according to the Meriden Record-Journal.
Cox will leave the company, a Sanofi spokesperson confirmed to FiercePharma. According to the Record-Journal, however, Cox claims she was forced out and has contacted an attorney. The publication also reported that Daniel Adams, former Protein Sciences head of business development, has been terminated. Adams cofounded Biogen in 1976, according to his profile on Protein Sciences’ website.
A Sanofi spokesperson said “Protein Sciences has been successfully and fully integrated into Sanofi Pasteur and, as such, there is no role of CEO for Protein Sciences. Sanofi Pasteur has acted in accordance with all obligations related to the Protein Sciences acquisition.”
Cox, who had been Protein Sciences’ CEO for 7 years, served as transition task force leader after the buyout, according to her LinkedIn profile. She served in managerial roles at Protein Sciences for nearly 20 years.
Sanofi picked up Protein Sciences last year after falling short in attempts to purchase Medivation and Actelion, bringing in an FDA-approved influenza vaccine that’s made with insect cells in an egg-free process. Sanofi Pasteur is the world’s No. 1 flu vaccine distributor and makes tens of millions of flu vaccine doses with eggs each year.
At the time, Sanofi Pasteur head David Loew said the purchase will allow the vaccines division of the global pharma giant to “broaden our flu portfolio with the addition of a non-egg based vaccine.” Cox praised Sanofi at the time of the buyout, saying she expected the company’s expertise in flu vaccines would help Flublok, its vaccine that hadn’t gained much traction in the market.
The outgoing CEO has long maintained Protein Sciences’ technology is superior to existing vaccines. When the Connecticut biotech won FDA approval for its FluBlok Quadrivalent back in 2016, Cox told FiercePharma she felt the company’s vaccine would be “the product of choice in time.”
“Even influenza vaccine manufacturers are recognizing that, over time, the egg-based production process will become obsolete and will be replaced with a more modern production process,” she said.
By Eric Sagonowsky
Source: Fierce Pharma
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
